Business
ASX to rise, Pfizer bolsters vaccine bets – The Australian Financial Review
Australian shares are poised to open lower after Wall Street shares sold off late in the session amid concerns surging virus cases will prompt wider lockdowns.
Pfizer and its partner BioNTech plan to submit the data to other regulatory agencies around the world and submit data from the study to a peer-reviewed scientific journal.
Pfizer reiterated that it expects to make as many as 50 million vaccine doses this year, enough to protect 25 million people, and then produce up to 1.3 billion doses in 2021.
“In my view, what stocks have not fully priced is more likely to be the 6+ month outlook that could benefit from expedited vaccine availability as opposed…
-
Noosa News18 hours agoMan dies in Brisbane crash, women and girl rushed to hospital
-
Noosa News24 hours agoChilling new details emerge in terrifying childcare centre incident in Peregian Springs on the Sunshine Coast
-
Business23 hours agoAre BHP shares are buy after its results?
-
Business13 hours agoprofit up 7%, guidance strong